Voice Articles
Combination CDK4/6 and Fulvestrant Has Survival Benefits in Late-Stage Breast Cancer
Combining a CDK4/6 inhibitor and fulvestrant improves overall survival consistently among patients with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer, according to a U.S. Food and Drug Administration (FDA) analysis. The agency reported the findings in Lancet Oncology.